Skip to main content
. 2020 Jun 11;1(3):100068. doi: 10.1016/j.jtocrr.2020.100068

Figure 3.

Figure 3

(A) OS of BRCA-positive patients with NSCLC according to pathogenic BRCA mutation or VUS. (B) OS of BRCA-positive (deleterious plus VUS) patients with NSCLC according to TP53 comutation present or absent. OS, overall survival; VUS, variant of unknown significance.